The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin

BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose‐limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bril, Sandra I., Al‐Mamgani, Abrahim, Chargi, Najiba, Remeijer, Peter, Devriese, Lot A., de Boer, Jan Paul, de Bree, Remco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298001/
https://www.ncbi.nlm.nih.gov/pubmed/34713519
http://dx.doi.org/10.1002/hed.26919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298001/
https://www.ncbi.nlm.nih.gov/pubmed/34713519
http://dx.doi.org/10.1002/hed.26919

Ejemplares similares